Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALL09 - Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult Acute Lymphoblastic Leukaemia

Trial Profile

ALL09 - Phase II Study of Blinatumomab as Induction Therapy in Adolescent and Young Adult Acute Lymphoblastic Leukaemia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms The SUBLIME Study
  • Most Recent Events

    • 12 Dec 2023 Results from this and other study assessing impact of blin on outcomes in genomic cohorts, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Primary endpoint (To assess the rate of minimal residual disease (MRD) negativity, where MRD negativity is defined as no presence of leukaemic blasts in blood or bone marrow sample as determined by EuroMRD accredited q-pcr analysis) has been met according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 13 Dec 2022 Results assessing whether the substitution of standard multi-agent cytotoxics with blinatumomab in protocol I phase 2 (consolidation) of a BFM based protocol in de novo AYA CD19+ ALL would be associated with improved day 79 MRD negativity rates and subsequent improvements in DFS and OS when compared to the ALL06 trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top